INT28035

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1986
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 20
Total Number 20
Disease Relevance 6.90
Pain Relevance 5.72

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Mention Frequency
CSF 3
hypothalamus 3
neurohypophysis 2
ventricles 1
liver 1


Pain Term Frequency Confidence Heat
Catecholamine 7 100.00 Very High Very High Very High
agonist 38 99.40 Very High Very High Very High
Dopamine 7 99.34 Very High Very High Very High
Enkephalin 19 99.28 Very High Very High Very High
Pain 9 99.28 Very High Very High Very High
anesthesia 9 98.76 Very High Very High Very High
amygdala 2 98.14 Very High Very High Very High
Opioid 14 98.08 Very High Very High Very High
opioid receptor 7 97.58 Very High Very High Very High
Hippocampus 38 96.56 Very High Very High Very High
Disease Term Frequency Confidence Heat
Hyponatremia 1 99.92 Very High Very High Very High
Syndrome 4 99.64 Very High Very High Very High
Heart Rate Under Development 1 99.60 Very High Very High Very High
Neurogenic Diabetes Insipidus 1 99.36 Very High Very High Very High
Pain 5 99.28 Very High Very High Very High
Stress 174 99.08 Very High Very High Very High
Nociception 5 98.88 Very High Very High Very High
Pressure And Volume Under Development 1 98.56 Very High Very High Very High
Cirrhosis 1 97.64 Very High Very High Very High
Anxiety Disorder 20 97.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results show an involvement of the SFO in the mechanism of osmotic activation of putative vasopressin (AVP)-secreting neurons in the PVN.
Localization (secreting) of AVP in PVN
1) Confidence 0.78 Published 1989 Journal Neurosci. Lett. Section Abstract Doc Link 2710398 Disease Relevance 0 Pain Relevance 0.33
From the hippocampus, stimuli which evoke a fear response will synapse with neurons in the amygdala sending efferent projections to the paraventricular nucleus (PVN) of the hypothalamus which secretes corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) [11].
Localization (secretes) of AVP in hypothalamus associated with anxiety disorder, hippocampus and amygdala
2) Confidence 0.78 Published 2009 Journal J Ocul Biol Dis Infor Section Body Doc Link PMC2723676 Disease Relevance 1.99 Pain Relevance 0.56
OBJECTIVE: Stress- and pain-related stimuli cause a release of vasopressin (AVP) and oxytocin (OT) into the cerebrospinal fluid (CSF) and extracellular fluid of the brain in various animal species.
Localization (release) of AVP in cerebrospinal fluid associated with stress and pain
3) Confidence 0.78 Published 2007 Journal Endocr Regul Section Abstract Doc Link 18257651 Disease Relevance 0.20 Pain Relevance 0.18
The aim of the study was to investigate the effect of stimulation of the nociceptive afferent terminals in the tooth pulp on the release of AVP and OT into CSF in rats under chloralose anesthesia.
Localization (release) of AVP in CSF associated with nociception and anesthesia
4) Confidence 0.78 Published 2007 Journal Endocr Regul Section Abstract Doc Link 18257651 Disease Relevance 0.27 Pain Relevance 0.19
Surgery causes the release of catecholamines, renin, angiotensin, and AVP that lead to a redistribution of renal blood flow and a decrease in GFR.
Localization (release) of AVP in blood associated with catecholamine
5) Confidence 0.78 Published 2006 Journal Anesthesiology clinics Section Abstract Doc Link 17240605 Disease Relevance 0.81 Pain Relevance 0.23
As a new class of therapeutic agents, orally active AVP analogs could be used to treat several human pathophysiological conditions including neurogenic diabetes insipidus, the syndrome of inappropriate secretion of AVP (SIADH), congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome, dysmenorrhea, and ocular hypertension.
Localization (secretion) of AVP in liver associated with hyponatremia, pressure and volume under development, heart rate under development, cirrhosis, syndrome, neurogenic diabetes insipidus, dismenorea, ocular hypertension and disorder of lipid metabolism
6) Confidence 0.78 Published 2002 Journal Prog. Brain Res. Section Abstract Doc Link 12436935 Disease Relevance 0.88 Pain Relevance 0.16
To elucidate mechanisms responsible for central HS-induced decrease in RSNA, possible involvement of arterial baroreceptors and peripheral arginine vasopressin (AVP) secreted from the posterior pituitary gland was examined using sinoaortic denervated (SAD) rats and non-peptide vasopressin receptor antagonists.
Localization (secreted) of AVP in gland associated with antagonist
7) Confidence 0.78 Published 1999 Journal J. Auton. Nerv. Syst. Section Abstract Doc Link 10412831 Disease Relevance 0 Pain Relevance 0.25
Previous studies have suggested an involvement of enkephalins in regulation of oxytocin (OXT) and vasopressin (AVP) release, which seems to disagree with the very low affinities of Met- and Leu-enkephalin for the kappa opioid receptor.
Localization (release) of AVP associated with kappa opioid receptor and enkephalin
8) Confidence 0.78 Published 1994 Journal J. Neuroendocrinol. Section Abstract Doc Link 8025568 Disease Relevance 0 Pain Relevance 0.59
The last observation is significant, because higher doses of ghrelin/GHS evoke ACTH, cortisol, and prolactin secretion acutely in humans and animals, putatively by inducing hypothalamic secretion of one or both primary ACTH-releasing peptides, corticotrophin-releasing hormone (CRH), and arginine vasopressin (AVP) [272, 274–278].
Localization (secretion) of AVP
9) Confidence 0.78 Published 2010 Journal International Journal of Peptides Section Body Doc Link PMC2925380 Disease Relevance 0.21 Pain Relevance 0.03
Neurosecretory SON cells were identified by antidromic invasion from the neurohypophysis and classified as AVP secreting on the basis of spontaneous activity patterns and responses to arterial baroreceptor activation.
Localization (secreting) of AVP in neurohypophysis
10) Confidence 0.78 Published 1987 Journal Am. J. Physiol. Section Abstract Doc Link 3618824 Disease Relevance 0.08 Pain Relevance 0.16
Secretion of vasopressin (AVP) and oxytocin (OT) was produced by either a Ca2+-ionophore or with electrical stimulation or by K+-induced depolarization.
Localization (Secretion) of AVP
11) Confidence 0.78 Published 1986 Journal Exp Brain Res Section Abstract Doc Link 3514253 Disease Relevance 0 Pain Relevance 0.58
Further, dopamine had no effect on the K+-induced AVP release although a crude extract of the pars intermedia abolished the electrically-evoked and reduced considerably the potassium-evoked AVP release.
Localization (release) of AVP in pars intermedia associated with dopamine
12) Confidence 0.78 Published 1986 Journal Exp Brain Res Section Abstract Doc Link 3514253 Disease Relevance 0 Pain Relevance 0.66
Opioid receptors in the neurohypophysis are predominantly of the kappa-subtype and selective kappa-agonists suppress electrically evoked release of oxytocin (OXT) and vasopressin (AVP).
Localization (release) of AVP in neurohypophysis associated with agonist and opioid receptor
13) Confidence 0.78 Published 1988 Journal Brain Res. Section Abstract Doc Link 2902908 Disease Relevance 0 Pain Relevance 0.45
The results demonstrated that oxotremorine stimulated muscarinic receptors in the hypothalamic SON and PVN, released AVP and induced an antidiuretic effect through AVP-receptors in the kidney.
Localization (released) of AVP in kidney
14) Confidence 0.68 Published 1989 Journal Jpn. J. Pharmacol. Section Abstract Doc Link 2747038 Disease Relevance 0 Pain Relevance 0.16
Under environmental or psychological stressful conditions, neurons in the paraventricular nucleus (PVN) of the hypothalamus secrete corticotropin-releasing hormone/factor (CRH/CRF) and arginine-vasopressin (AVP), which in turn, stimulate the secretion of
Localization (secrete) of AVP in hypothalamus
15) Confidence 0.68 Published 2007 Journal Neural Plasticity Section Body Doc Link PMC1906869 Disease Relevance 1.15 Pain Relevance 0.14
Under environmental or psychological stressful conditions, neurons in the paraventricular nucleus (PVN) of the hypothalamus secrete corticotropin-releasing hormone/factor (CRH/CRF) and arginine-vasopressin (AVP), which in turn, stimulate the secretion of
Localization (secretion) of AVP in hypothalamus
16) Confidence 0.68 Published 2007 Journal Neural Plasticity Section Body Doc Link PMC1906869 Disease Relevance 1.17 Pain Relevance 0.14
Release of both OXT and AVP evoked by K+-depolarisation was inhibited by the kappa-agonists U-50,488H (34% and 45% respectively) and dynorphin A1-13 (68% and 51% respectively).
Localization (Release) of AVP associated with dynorphin and agonist
17) Confidence 0.68 Published 1988 Journal Brain Res. Section Abstract Doc Link 2902908 Disease Relevance 0 Pain Relevance 0.57
CONCLUSION: It was found that noxious stimulus from the tooth pulp is not a factor affecting significantly AVP and OT release into CSF.


Localization (release) of AVP in CSF
18) Confidence 0.68 Published 2007 Journal Endocr Regul Section Body Doc Link 18257651 Disease Relevance 0.06 Pain Relevance 0
Electric tooth pulp stimulation exerted no effect on AVP and OT release into the fluid perfusing the cerebral ventricles during stimulation.
Localization (release) of AVP in ventricles
19) Confidence 0.68 Published 2007 Journal Endocr Regul Section Body Doc Link 18257651 Disease Relevance 0.07 Pain Relevance 0
These results suggest that endogenously-released ANG II and opioid peptides in the PVN and ANG II in the SON regulate urine production mediated through increased AVP release.
Localization (release) of AVP in urine associated with opioid
20) Confidence 0.68 Published 1996 Journal Jpn. J. Pharmacol. Section Abstract Doc Link 8791172 Disease Relevance 0 Pain Relevance 0.36

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox